Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the Pharma & Biotech edition of the IP Think Tank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: http://thinkipstrategy.com/subscribe/

Highlights this week included:

US: CAFC affirms rejection of claim reciting broad genus of monoclonal antibodies for failure to satisfy written description requirement: In re Alonso (Holman’s Biotech IP Blog), (Patent Docs) (Patent Prospector) (Hal Wegner) (Patently-O)

General

The Medical Innovation Prize Fund and the WTO TRIPS Agreement (GenericsWeb)

India: Opening of Indian economy and India’s Patents (Amendment) Act 2005: their impact on pharmaceuticals: (IP Down Under)

Spain: SPCs in Spain (The SPC Blog)

Switzerland: More on SPCs in Switzerland (The SPC Blog)

US: Applying Bilski to biotechnology and the life sciences (Patently-O)

US: CAFC affirms rejection of claim reciting broad genus of monoclonal antibodies for failure to satisfy written description requirement: In re Alonso (Holman’s Biotech IP Blog), (Patent Docs) (Patent Prospector) (Hal Wegner) (Patently-O)

US: Paying off your generic drug competition? No problem: In re Ciprofloxacin Hydrochloride Antitrust Litigation (Patent Baristas)

US: FTC Commissioner speaks out on follow-on biologics – current initiatives and long-term goals (FDA Law Blog)

US: Hatch-Waxman Act-related lawsuits likely to drop, but generic companies may start to challenge biotechnology patents, says David Pritikin (Law360)

US: Sequenom sues rival genetic research company Ibis Biosciences alleging infringement of DNA analysis patents (Law360)

Products

Biaxin (Clarithromycin) – US: Opposing Federal Circuit preliminary injunction standards: Abbott Laboratories v. Sandoz, Inc (Patent Docs) (PATracer)

Boniva (Ibandronic acid) – US: Hoffman La Roche files third patent infringement lawsuit against Orchid over generic Boniva (GenericsWeb)

Carbatrol (Carbamazepine) – US: Federal Judge grants summary judgment of noninfringement to Corepharma in Carbatrol patent dispute with Shire Laboratories (Law360)

Effexor (Venlafaxine) – US: Wyeth settles with fourth drug company, Anchen Pharmaceuticals, over generic Effexor (Law360)

Fentora (Fentanyl) – US: Cephalon sues Barr again over generic Fentora ANDA (Law360)

Focalin (Dexmethylphenidate) – US: Federal judge dismisses claims of wilful infringement from four separate actions brought by Celgene and Novartis to stop Teva, Actavis and others from marketing generic Focalin (Law360)

Plavix (Clopidogrel) – Canada: Supreme Court confirms Plavix patent despite evergreening charges: Apotex v Sanofi-Synthelabo Canada (Patently-O)

Prevacid (Lansoprazole) – US: Oral argument in inequitable conduct case Takeda Pharma v Teva Pharma to be heard 5 November (Summary of arguments from both parties) (PATracer)

Razadyne (Galantamine) – US: Claims not obvious over prior art aren’t enabled by that art: Janssen Pharma v Teva (PATracer)

Rilutek (Riluzole) – US: Eight factors for determining ‘undue experimentation’ to defeat anticipation in the US: Impax v Aventis (IP Updates)

Stalevo (Carbidopa, Levodopa, Entacapone) – US: Wockhardt challenges patent for Stalevo originated by Orion and marketed by Novartis (GenericsWeb)

Topamax (Topiramate) – US: Court trims Daiichi’s award of costs: Ortho-McNeil v Mylan Labs (PATracer)

TriCor (Fenofibrate) – US: Abbott sues Biovail over generic TriCor (Law360)

Ultram (Tramadol) – Ortho-McNeil Janssen files another patent infringement suit against Impax over generic Ultram ANDA (Law360)